Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Robert McWhirter
Cardiol TherapeuticsCRDL.TOHOLDFeb 15, 2019
He has met management twice and they had their IPO in mid-December. They have looked into the use of CBD to use as an anti-inflammatory for heart patients. They are working on developing synthetic CBD. They think they could produce 1 millions grams of CBD this year. This creates a great opportunity and they have enough technology to advance their strategy. If they can sell the CBC, the company is fairly valued.
Robert McWhirterUnknown
$6.62
Stock price when the opinion was issued
$1.46
As of Jun 12, 2026. Market Open.
biotechnology
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
BUY
COVID-19 heart issues? The company makes a synthetic CBD. Their original work saw CBD helped to reduce inflammation of the heart. It is expected they will start to re-purpose their product for COVID patients. This would help accelerate testing by about 2 years. This could lead to product being sold in Canada very quickly. A great opportunity.
Robert McWhirterOwned
biotechnology
